{
    "clinical_study": {
        "@rank": "164777", 
        "arm_group": [
            {
                "arm_group_label": "Carvedilol (for Aim 3 only)", 
                "arm_group_type": "Experimental", 
                "description": "Eligible case subjects from aims 1-2 will participate in a randomized crossover study where each subject will receive carvedilol and prazosin for 8 weeks each(under randomized treatment sequence) with a 1 week washout period included in between treatments.\nThe first arm will include subjects that are assigned to the randomization sequence: Carvedilol x 8 weeks (titrated up to 50 mg po bid), washout x 1 week, Prazosin x 8 weeks (titrated up to 16 mg daily)"
            }, 
            {
                "arm_group_label": "Prazosin (for Aim 3 only)", 
                "arm_group_type": "Active Comparator", 
                "description": "Eligible case subjects from aims 1-2 will participate in a randomized crossover study where each subject will receive carvedilol and prazosin for 8 weeks each(under randomized treatment sequence) with a 1 week washout period included in between treatments.\nThe first arm will include subjects that are assigned to the randomization sequence: Prazosin x 8 weeks, washout x 1 week, Carvedilol x 8 weeks"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is 1) to determine what physiologic factors (extracellular fluid\n      overload or vasoconstriction) contribute more to increased blood pressure levels between\n      dialysis treatments in hemodialysis patients whose blood pressure increases and decreases\n      during hemodialysis and 2) to determine whether carvedilol provides better control of blood\n      pressure between dialysis treatments than prazosin in patients whose blood  pressure\n      increases during dialysis."
        }, 
        "brief_title": "Mechanisms of Increased Ambulatory Blood Pressure in Patients With Intradialytic Hypertension", 
        "completion_date": {
            "#text": "July 2017", 
            "@type": "Anticipated"
        }, 
        "condition": "Intradialytic Hypertension", 
        "condition_browse": {
            "mesh_term": "Hypertension"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria (for Aims 1 and 2):\n\n          -  age more than 18 years\n\n          -  Hypertension defined as systolic blood pressure more than 140 mmHg before dialysis or\n             more than 130 mmHg after dialysis\n\n          -  For case subjects with intradialytic hypertension:  systolic blood pressure increase\n             more than 10 mmHg from pre to post dialysis in at least 4 out of 6 screening\n             treatments\n\n          -  For control subjects: systolic blood pressure decrease more than 10 mmHg from pre to\n             post dialysis in at least 4 out of 6 screening treatments\n\n        Inclusion criteria for Aim 3 includes the case subjects described above.\n\n        Exclusion Criteria:\n\n        For Aims 1 and 2:\n\n          -  Hemodialysis vintage less than 1 month\n\n          -  Amputated arm or leg\n\n          -  Presence of cardiac defibrillator or pacemaker\n\n          -  Presence of large metal prosthesis\n\n          -  Failure to achieve dry weight\n\n        For Case subjects participating in Aim 3:\n\n          -  Patients with a specific indication for beta blocker therapy including systolic heart\n             failure, history of myocardial infarction, history of tachyarrhythmia or angina being\n             managed with beta blocker therapy.\n\n          -  Patients with contraindications to beta blockade including bradycardia (heart rate\n             less than 60 beats per minute) while not on a pulse lowering drug, severe reactive\n             airway disease, prior intolerance to beta blocker therapy\n\n          -  Prior intolerance to alpha blocker therapy"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "80 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "140", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 18, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01862497", 
            "org_study_id": "STU 052012-029"
        }, 
        "intervention": {
            "arm_group_label": [
                "Carvedilol (for Aim 3 only)", 
                "Prazosin (for Aim 3 only)"
            ], 
            "intervention_name": "Carvedilol vs. Prazosin", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Carvedilol", 
                "Prazosin"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Intradialytic Hypertension", 
            "Hemodialysis", 
            "Hypertension", 
            "Extracellular Volume", 
            "Endothelial Cell Dysfunction", 
            "Endothelin 1", 
            "Carvedilol"
        ], 
        "lastchanged_date": "May 21, 2013", 
        "location": {
            "contact": {
                "email": "peter.vanburen@utsouthwestern.edu", 
                "last_name": "Peter N Van Buren, MD", 
                "phone": "214-645-8293"
            }, 
            "facility": {
                "address": {
                    "city": "Dallas", 
                    "country": "United States", 
                    "state": "Texas", 
                    "zip": "75390"
                }, 
                "name": "University of Texas Southwestern Medical Center at Dallas"
            }, 
            "investigator": {
                "last_name": "Peter N Van Buren, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "Mechanism of Increased Ambulatory Blood Pressure in Patients With Intradialytic Hypertension and Hemodialysis Controls: A Case Control Study and Crossover Trial Comparing Carvedilol and Prazosin Hydrochloride", 
        "other_outcome": [
            {
                "measure": "Change in Vascular Resistance from pre to post dialysis", 
                "safety_issue": "No", 
                "time_frame": "Expected recruitment is 4-5 years"
            }, 
            {
                "measure": "Change in Asymmetric Dimethylarginine From pre to post dialysis", 
                "safety_issue": "No", 
                "time_frame": "Expected recruitment is 4-5 years"
            }, 
            {
                "measure": "Change in Angiotensin II from pre to post dialysis", 
                "safety_issue": "No", 
                "time_frame": "Expected recruitment is 4-5 years"
            }
        ], 
        "overall_contact": {
            "email": "peter.vanburen@utsouthwestern.edu", 
            "last_name": "Peter N Van Buren, MD", 
            "phone": "214-645-8293"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "July 2017", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Ratio of Extracellular Body Water to Total Body Water", 
            "safety_issue": "No", 
            "time_frame": "Expected recruitment is 4-5 years"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01862497"
        }, 
        "responsible_party": {
            "investigator_affiliation": "University of Texas Southwestern Medical Center", 
            "investigator_full_name": "Peter Van Buren", 
            "investigator_title": "Instructor", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "measure": "Change in Endothelin-1 from pre to post dialysis", 
            "safety_issue": "No", 
            "time_frame": "Expected recruitment is 4-5 years"
        }, 
        "source": "University of Texas Southwestern Medical Center", 
        "sponsors": {
            "collaborator": {
                "agency": "American Heart Association", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "University of Texas Southwestern Medical Center", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "January 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2013"
    }
}